Calidi Biotherapeutics (CLDI)

• Market cap: $5.45M
• 1 day: 0.69%
• 5 days: -1.13%
• 1 month: -25.45%
• 3 months: -43.25%
• 6 months: -51.26%
• Year to date: -35.56%
• 1 year: -93.47%
• 5 years: -99.94%
• 10 years: -99.94%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.

Employees: 28